97. Ulcerative colitis Clinical trials / Disease details

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab , adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway
2	NCT01090154 (ClinicalTrials.gov)	December 1, 2010	15/3/2010	Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study	Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study	Ulcerative Colitis	Drug: Cimzia	University of Washington	UCB Pharma;University of Pennsylvania	Completed	18 Years	75 Years	All	27	Phase 2	United States